Business Description
Defence Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA24463V1013
Compare
Compare
Traded in other countries / regions
DTC.CanadaDTC.GermanyDTCFF.USA IPO Date
2021-05-07Description
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | -9.7 | |||||
| Debt-to-Equity | -0.45 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -38.6 | |||||
| 3-Year EPS without NRI Growth Rate | -39.7 | |||||
| 3-Year FCF Growth Rate | -5.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.05 | |||||
| 9-Day RSI | 40.81 | |||||
| 14-Day RSI | 41.62 | |||||
| 3-1 Month Momentum % | 11.32 | |||||
| 6-1 Month Momentum % | -42.16 | |||||
| 12-1 Month Momentum % | -77.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.04 | |||||
| Quick Ratio | 0.04 | |||||
| Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.9 | |||||
| Shareholder Yield % | -7.73 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -1405.4 | |||||
| ROIC % | -727.46 | |||||
| 3-Year ROIIC % | -509.36 | |||||
| ROC (Joel Greenblatt) % | -5966.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.36 | |||||
| EV-to-EBITDA | -2.38 | |||||
| EV-to-FCF | -8.74 | |||||
| Earnings Yield (Greenblatt) % | -42.32 | |||||
| FCF Yield % | -12.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Defence Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.26 | ||
| Beta | 1.24 | ||
| 3-Year Sharpe Ratio | -1.02 | ||
| 3-Year Sortino Ratio | -1.3 | ||
| Volatility % | 35.14 | ||
| 14-Day RSI | 41.62 | ||
| 14-Day ATR (C$) | 0.021256 | ||
| 20-Day SMA (C$) | 0.538 | ||
| 12-1 Month Momentum % | -77.74 | ||
| 52-Week Range (C$) | 0.48 - 2.55 | ||
| Shares Outstanding (Mil) | 47.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Defence Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Defence Therapeutics Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Defence Therapeutics Inc Frequently Asked Questions
What is Defence Therapeutics Inc(XCNQ:DTC)'s stock price today?
The current price of XCNQ:DTC is C$0.52. The 52 week high of XCNQ:DTC is C$2.55 and 52 week low is C$0.48.
When is next earnings date of Defence Therapeutics Inc(XCNQ:DTC)?
The next earnings date of Defence Therapeutics Inc(XCNQ:DTC) is .
Does Defence Therapeutics Inc(XCNQ:DTC) pay dividends? If so, how much?
Defence Therapeutics Inc(XCNQ:DTC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers